| Name: | Dapagliflozin Bromomethanone |
| Catalogue No. | VE006597 |
| CAS No. | 461432-22-4 |
| Molecular Formula | C15H12BrClO2 |
| Molecular Weight | 339.61 |
| Status | In-stock |
| IUPAC Name | (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone |
| Synonyms | Dapagliflozin Impurity 6 |
| Description | Dapagliflozin Bromomethanone (CAS No.: 461432-22-4) or Dapagliflozin Impurity 6 is an intermediate in the synthesis of Dapagliflozin which shows a strong biological activity. Dapagliflozin is an orally ingested sodium-glucose co-transporter-2 (SGLT2) inhibitor evaluated in the management of patients having type 2 diabetes. Dapagliflozin lowers renal glucose reabsorption by blocking the transporter protein SGLT2. |
| References | Shao, Hua, et al. “(5-Bromo-2-Chlorophenyl)(4-Ethoxyphenyl)Methanone.” Acta Crystallographica Section E Structure Reports Online, vol. 65, no. 12, Nov. 2009, pp. o3071–71,https://doi.org/10.1107/s1600536809047151.Plosker, Greg L. “Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes.” Drugs, vol. 74, no. 18, Nov. 2014, pp. 2191–209,https://doi.org/10.1007/s40265-014-0324-3. |
